Co-Diagnostics Reports Full-Year 2025 Results

Co-Diagnostics, Inc. reported full-year 2025 financial results for the year ended December 31, 2025. Revenue was $0.6 million versus $3.9 million in 2024, with operating expenses of $50.6 million including a non-cash impairment charge of $18.9 million from revaluation of intangible assets.

The company posted an operating loss of $50.2 million and a net loss of $46.9 million, or $35.25 per share. Adjusted EBITDA loss was $28.0 million. Cash, cash equivalents, and marketable investment securities totaled $11.9 million at December 31, 2025.

Operationally, Co-Diagnostics advanced CoSara and CoMira joint ventures, progressed clinical evaluations of an upper respiratory multiplex test, expanded its AI business unit within the Co-Dx Primer AI platform, and added to its IP portfolio with international patents.